Alexion Pharmaceuticals, Inc. shares Americares mission to provide urgently needed relief to people affected by disasters around the globe. The company and its employees have helped us maintain the expertise and capabilities necessary to launch emergency responses swiftly and effectively.
Alexion has been an engaged partner to Americares since 2001. Following the 9/11 terrorist attacks, the company contributed to our Heroes Fund to support the family members of New York City firefighters, police officers and Port Authority employees who lost their lives. Since then, Alexion and its employees have supported responses to several specific disasters including the Pacific earthquake and tsunami in 2011, Hurricane Sandy in 2012, the earthquake in Nepal in 2015, flooding in India in 2017 and Hurricanes Harvey, Irma and Maria during the 2017 hurricane season.
Alexion is an Americares Emergency Response Partner, providing key resources that allow us to maintain a response platform of medicines, supplies and emergency response experts. Thanks to Alexion and the other members of the AERP, when disasters strike, Americares can launch robust responses at a moment’s notice, delivering critical medicines and emergency supplies virtually anywhere in the world.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). In addition, the company is developing two late-stage therapies, a second complement inhibitor and a copper-binding agent for Wilson disease. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. Alexion has been named to the Forbes list of the World’s Most Innovative Companies seven years in a row and is headquartered in Boston, Massachusetts’ Innovation District. The company also has offices around the globe and serves patients in more than 50 countries. Further information about Alexion can be found at: www.alexion.com.